FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129128401> ?p ?o ?g. }

• W2129128401 endingPage "655" @default.
• W2129128401 startingPage "648" @default.
• W2129128401 abstract "Background The prevention of medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome has demonstrated the ability of molecular diagnosis and prophylactic surgery to improve patient outcomes. However, the other major neoplasia associated with multiple endocrine neoplasia type 2, phaeochromocytoma, is not as well characterised in terms of occurrence and treatment outcomes. In this study, we aimed to systematically characterise the outcomes of management of phaeochromocytoma associated with multiple endocrine neoplasia type 2. Methods This multinational observational retrospective population-based study compiled data on patients with multiple endocrine neoplasia type 2 from 30 academic medical centres across Europe, the Americas, and Asia. Patients were included if they were carriers of germline pathogenic mutations of the RET gene, or were first-degree relatives with histologically proven medullary thyroid cancer and phaeochromocytoma. We gathered clinical information about patients' RET genotype, type of treatment for phaeochromocytoma (ie, unilateral or bilateral operations as adrenalectomy or adrenal-sparing surgery, and as open or endoscopic operations), and postoperative outcomes (adrenal function, malignancy, and death). The type of surgery was decided by each investigator and the timing of surgery was patient driven. The primary aim of our analysis was to compare disease-free survival after either adrenal-sparing surgery or adrenalectomy. Findings 1210 patients with multiple endocrine neoplasia type 2 were included in our database, 563 of whom had phaeochromocytoma. Treatment was adrenalectomy in 438 (79%) of 552 operated patients, and adrenal-sparing surgery in 114 (21%). Phaeochromocytoma recurrence occurred in four (3%) of 153 of the operated glands after adrenal-sparing surgery after 6–13 years, compared with 11 (2%) of 717 glands operated by adrenalectomy (p=0·57). Postoperative adrenal insufficiency or steroid dependency developed in 292 (86%) of 339 patients with bilateral phaeochromocytoma who underwent surgery. However, 47 (57%) of 82 patients with bilateral phaeochromocytoma who underwent adrenal-sparing surgery did not become steroid dependent. Interpretation The treatment of multiple endocrine neoplasia type 2-related phaeochromocytoma continues to rely on adrenalectomies with their associated Addisonian-like complications and consequent lifelong dependency on steroids. Adrenal-sparing surgery, a highly successful treatment option in experienced centres, should be the surgical approach of choice to reduce these complications. Funding European Union, German Cancer Foundation, Arthur Blank Foundation, Italian Government, Charles University, Czech Ministry of Health, Nanjing Military Command, National Science Centre Poland, National Research Council for Scientific and Technological Development, and State of São Paulo Research Foundation." @default.
• W2129128401 created "2016-06-24" @default.
• W2129128401 creator A5001137920 @default.
• W2129128401 creator A5003851108 @default.
• W2129128401 creator A5004673392 @default.
• W2129128401 creator A5005167165 @default.
• W2129128401 creator A5006267802 @default.
• W2129128401 creator A5006673441 @default.
• W2129128401 creator A5006771123 @default.
• W2129128401 creator A5006802357 @default.
• W2129128401 creator A5007399848 @default.
• W2129128401 creator A5011116564 @default.
• W2129128401 creator A5011938143 @default.
• W2129128401 creator A5012902340 @default.
• W2129128401 creator A5014243379 @default.
• W2129128401 creator A5014580246 @default.
• W2129128401 creator A5014689729 @default.
• W2129128401 creator A5015699920 @default.
• W2129128401 creator A5019978786 @default.
• W2129128401 creator A5020202637 @default.
• W2129128401 creator A5021409654 @default.
• W2129128401 creator A5023770804 @default.
• W2129128401 creator A5026090512 @default.
• W2129128401 creator A5027181031 @default.
• W2129128401 creator A5030612530 @default.
• W2129128401 creator A5031543944 @default.
• W2129128401 creator A5031571885 @default.
• W2129128401 creator A5032995631 @default.
• W2129128401 creator A5033884890 @default.
• W2129128401 creator A5034487665 @default.
• W2129128401 creator A5037688565 @default.
• W2129128401 creator A5038041992 @default.
• W2129128401 creator A5038322204 @default.
• W2129128401 creator A5038452239 @default.
• W2129128401 creator A5041056118 @default.
• W2129128401 creator A5043356864 @default.
• W2129128401 creator A5047413937 @default.
• W2129128401 creator A5048767543 @default.
• W2129128401 creator A5048920630 @default.
• W2129128401 creator A5051447608 @default.
• W2129128401 creator A5051798949 @default.
• W2129128401 creator A5057088905 @default.
• W2129128401 creator A5057117005 @default.
• W2129128401 creator A5058845564 @default.
• W2129128401 creator A5058896363 @default.
• W2129128401 creator A5061872503 @default.
• W2129128401 creator A5062280504 @default.
• W2129128401 creator A5062378419 @default.
• W2129128401 creator A5064807457 @default.
• W2129128401 creator A5066361971 @default.
• W2129128401 creator A5070069839 @default.
• W2129128401 creator A5070644130 @default.
• W2129128401 creator A5070753363 @default.
• W2129128401 creator A5072976180 @default.
• W2129128401 creator A5074308093 @default.
• W2129128401 creator A5075024061 @default.
• W2129128401 creator A5076821793 @default.
• W2129128401 creator A5077452584 @default.
• W2129128401 creator A5078429982 @default.
• W2129128401 creator A5083346686 @default.
• W2129128401 creator A5088726832 @default.
• W2129128401 date "2014-05-01" @default.
• W2129128401 modified "2023-10-17" @default.
• W2129128401 title "Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study" @default.
• W2129128401 cites W1803116581 @default.
• W2129128401 cites W1988823135 @default.
• W2129128401 cites W1989888312 @default.
• W2129128401 cites W2007836147 @default.
• W2129128401 cites W2015402253 @default.
• W2129128401 cites W2030106346 @default.
• W2129128401 cites W2044761914 @default.
• W2129128401 cites W2064296340 @default.
• W2129128401 cites W2101005605 @default.
• W2129128401 cites W2111461847 @default.
• W2129128401 cites W2130645430 @default.
• W2129128401 cites W2136312033 @default.
• W2129128401 cites W2160863198 @default.
• W2129128401 cites W2161813607 @default.
• W2129128401 cites W2166320353 @default.
• W2129128401 cites W2172146290 @default.
• W2129128401 cites W2341242206 @default.
• W2129128401 cites W4248988283 @default.
• W2129128401 doi "https://doi.org/10.1016/s1470-2045(14)70154-8" @default.
• W2129128401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24745698" @default.
• W2129128401 hasPublicationYear "2014" @default.
• W2129128401 type Work @default.
• W2129128401 sameAs 2129128401 @default.
• W2129128401 citedByCount "121" @default.
• W2129128401 countsByYear W21291284012014 @default.
• W2129128401 countsByYear W21291284012015 @default.
• W2129128401 countsByYear W21291284012016 @default.
• W2129128401 countsByYear W21291284012017 @default.
• W2129128401 countsByYear W21291284012018 @default.
• W2129128401 countsByYear W21291284012019 @default.
• W2129128401 countsByYear W21291284012020 @default.
• W2129128401 countsByYear W21291284012021 @default.
• W2129128401 countsByYear W21291284012022 @default.
• W2129128401 countsByYear W21291284012023 @default.

• next